Crossmark

Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1

Crossref DOI link: https://doi.org/10.1186/s13023-020-01406-8

Published Online: 2020-05-24

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maekawa, Hirotsugu

Kawai, Shunsuke

Nishio, Megumi

Nagata, Sanae

Jin, Yonghui

Yoshitomi, Hiroyuki

Matsuda, Shuichi

Toguchida, Junya http://orcid.org/0000-0002-0184-9685
Funding

Funding for this research was provided by:

Scientific Research Grant from MEXT, Japan (18H02928)

Japan Agency for Medical Research and Development (18059412, 18bm0304004h0006, 18bm0104001h0006, 18bm0804006h0002)
License Information

Text and Data Mining valid from 2020-05-24

Version of Record valid from 2020-05-24
More Information

Article History

Received: 15 November 2019

Accepted: 11 May 2020

First Online: 24 May 2020

Ethics approval and consent to participate

: No human materials were used in this study, and all animal experiments were approved by the institutional animal committee of Kyoto University.

: Not applicable.

: The authors declare no conflicts of interest.

Document is current

Any future updates will be listed below